Jump to content
RemedySpot.com

ChronSeal multi-center study in Sweden and Norway finalized

Rate this topic


Recommended Posts

Guest guest
Posted

http://www.news-medical.net/news/20100428/ChronSeal-multi-center-study-in-Sweden\

-and-Norway-finalized.aspx

ChronSeal multi-center study in Sweden and Norway finalized

28. April 2010 03:01

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and

the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and

Kringle have jointly decided that the results will be publicly available on May

27th. At follow-up of the ChronVac-C® -study where patients now have started

treatment according to standard-of-care (interferon and ribavirin) all patients

(100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50

copies of virus/mL blood already at treatment week four. This type of rapid

treatment response is very unusual for patients infected with the hard to treat

form of HCV called genotype 1 and further underscores a role for ChronVac-C® in

a combination therapy.

The ChronVac-C®-study on patients chronically infected with hepatitis C virus

(HCV) of genotype 1 is, as has been previously reported, finalized and shows

that the therapeutic vaccine has good safety and shows positive clinical data.

Two patients in the ChronVac-C®-study have received an additional dose

approximately 6-12 months after the fourth vaccination and analysis of the

results are under way. Now six patients in the study have started treatment with

standard of care-therapy, i.e. interferon combined with ribavirin. Five of these

(83%) have responded quickly on the treatment with <50 virus copies/mL blood

already after four weeks (so called rapid viral response) in comparison to

normally only 10-15% rapid viral response after standard treatment only. This

unusually rapid reduction of virus in the blood indicates that there is a role

for ChronVac-C® in combination therapy. All six patients are now virus free and

the two patients who have already been treated for 24 weeks could at that time

stop therapy and are today considered cured. Also this good treatment outcome is

unusual for patients infected with HCV of genotype 1 where the normal treatment

time is 48 weeks and 40-50% of the patients are virus free after completing

their treatment.

" We are very happy over the results we have obtained in the ChronVac-C® study

and look forward with confidence to the results from the ChronSeal® study. An

intensive work is now ongoing with the continued clinical development. We look

forward with excitement to begin clinical studies that will take us closer to

final medicines " says Anders Vahlne, CEO of ChronTech Pharma.

SOURCE ChronTech

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...